Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02036528 |
Recruitment Status :
Terminated
First Posted : January 15, 2014
Last Update Posted : May 14, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetic Foot Ulcers | Drug: Gentamicin Topical Gel Drug: Ciprofloxacin Drug: Doxycycline | Phase 1 Phase 2 |
Infection of a diabetic foot ulcer (DFU) is a serious and common complication of diabetes and is among the most common diabetes-related cause of hospitalization and the leading cause of diabetes-associated lower limb amputation. The effectiveness of various systemic antibiotics, particularly the fluoroquinolones, in treating infected DFUs has been demonstrated.
An alternative or adjunct to systemic antibiotic treatment of infected DFU's is topical antibiotic treatment. Topical treatment would have the advantages of avoiding systemic adverse effects, providing increased target site concentration, and allowing the use of antibiotics not approved for systemic treatment.
AppliGel-G is a topically applied hydrogel formulation of gentamicin sulfate (GMS). Once in place the product remains in contact with the wound bed and releases Gentamicin to the wound bed.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I/II, Open Label, Controlled Study to Evaluate the Safety and Efficacy of AppliGel-G [Gentamicin Sulfate Topical Gel] for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers in Patients With Type 1 and Type 2 Diabetes |
Study Start Date : | January 2014 |
Actual Primary Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: AppliGel-G with oral Ciprofloxacin and Doxycycline
AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
|
Drug: Gentamicin Topical Gel Drug: Ciprofloxacin Drug: Doxycycline |
Active Comparator: Oral Ciprofloxacin and Doxycycline only
Ciprofloxacin and Doxycycline
|
Drug: Ciprofloxacin Drug: Doxycycline |
- Complete wound clearing of infection [ Time Frame: 28 days ]Proportion of subjects with foot ulcer infection completely cleared at or by 28 days of AppliGel-G treatment compared to proportion of subjects with foot ulcer infection completely cleared at or by 28 days of control treatment
- Incidence of infection cleared [ Time Frame: 28 days ]Incidence of infection cleared at Day 14
- DFU Volume % Change [ Time Frame: 28 days ]percent change in DFU volume, measured weekly and compared to baseline
- DFU Area % Change [ Time Frame: 28 days ]percent change in DFU area, measured weekly and compared to baseline

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is 18 years of age or older
- Subject has a mild to moderately infected (IDSA Mild or Moderate/ PEDIS Grade 2 or 3) diabetic foot ulcer and without a previous history of partial foot amputation.
- Subject has Diabetes Mellitus (type 1 or type 2).
- Wound area measurement between 1-25 cm2 and does not exceed 25 cm2.
- Subject is in general good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.
- Female subjects must have a negative urine pregnancy test at screening and be willing and able to use a medically acceptable method of birth control or declare that they are abstaining from sexual intercourse, from the screening visit through the study termination visit or be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal. Postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.
- Subject has either no renal failure or only mild renal failure (i.e.: glomerular filtration rate (GFR) must be above 60 mL/min/1.73m2)
- Subject is willing and committed to comply with the research protocol and complete all outcome measures.
- Subject is able to self-consent.
- Subject is able to speak and read English..
Exclusion Criteria:
- Subject is non-diabetic
- Subject's foot lesion(s) are of etiology other than diabetic neuropathy
- DFU is PEDIS Infection Grade 1 or 4
- Infected DFU measures >25 cm2
- The wound involves bone, tendon or joint damage not due to infection
- Wound with sinus tracts
- HbA1c>11%
- Subject with skin disorders unrelated to the ulcer that are presented adjacent to the wound
- Clinically significant arterial vascular disease based on Skin Perfusion Pressure System (SensiLase) measurement of skin perfusion pressure (SPP) of <30 mm Hg.
- Subject is receiving, or has received within one month prior to enrollment any treatment known to impair wound healing, including but not limited to: corticosteroids, immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.
- Known history of a significant medical disorder, which in the investigator's judgment contraindicates the subject's participation.
- Has active malignant disease of any kind. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
- Subjects who present with significant metabolic co morbidity that would preclude wound healing such as end stage renal failure, dialysis or severe liver dysfunction.
- Known hypersensitivity and/or allergy to gentamicin or the study oral antibiotics or related drugs.
- Drug or alcohol abuse (by history). 16 Subjects participating in any other trials in regards to the diabetic foot ulcer or antibiotic therapy.
17 History of myasthenia gravis 18 Any condition or use of prescribed medication in which participation in this study would impact the safety of the individual participant.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02036528
United States, District of Columbia | |
Georgetown University Hospital Center | |
Washington, District of Columbia, United States, 20007 | |
United States, Florida | |
GF Professional Research, Corp. | |
Miami Lakes, Florida, United States, 33016 | |
Florida Medical Center & Research, Inc. | |
Miami, Florida, United States, 33142 | |
United States, Georgia | |
Advanced Foot and Ankle Institute of Georgia LLC | |
Smyrna, Georgia, United States, 30080 | |
United States, Maryland | |
Union Memorial Hospital | |
Baltimore, Maryland, United States, 21218 | |
United States, Michigan | |
Detroit Clinical Research Center, PC | |
Farmington Hills, Michigan, United States, 48334 | |
United States, Utah | |
Utah Valley Medical Center | |
Provo, Utah, United States, 84604 |
Responsible Party: | Royer Biomedical, Inc. |
ClinicalTrials.gov Identifier: | NCT02036528 |
Other Study ID Numbers: |
CP-RBM-2011-001 DFU |
First Posted: | January 15, 2014 Key Record Dates |
Last Update Posted: | May 14, 2015 |
Last Verified: | May 2015 |
Foot Ulcer Diabetic Foot Gentamicins infection |
Diabetic Foot Foot Ulcer Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases |
Doxycycline Ciprofloxacin Gentamicins Anti-Bacterial Agents Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors |